CTRI/2011/08/001941已完成3 期
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome - ATLAS-ACS 2
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 15,527
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria:
- •Ages Eligible for Study: 18 Years and older. There is no upper age limit for this study.
- •Genders Eligible for Study: Both
- •Patients must be currently receiving aspirin therapy alone or in combination with a thienopyridine per national or local dosing recommendation
- •:Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital
排除标准
- •Exclusion Criteria:
- •Patient below 18 years of age.
- •Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding
- •Need for continued anticoagulant therapy
- •Significant renal impairment or known significant liver disease
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-2 - The ATLAS ACS 2 TIMI 51 TrialAcute Coronary Syndrome (ACS)MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2008-002708-25-SKJanssen-Cilag International N.V.16,000
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-1 - The ATLAS ACS 2 TIMI 51 TrialEUCTR2008-002708-25-HUJanssen-Cilag International N.V.16,000
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome - ATLAS ACS 2 TIMI 51EUCTR2008-002708-25-ITJanssen-Cilag International N.V.16,000
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-2 - The ATLAS ACS 2 TIMI 51 TrialAcute Coronary Syndrome (ACS)MedDRA version: 14.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-002708-25-DEJanssen-Cilag International N.V.16,000
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-2 - The ATLAS ACS 2 TIMI 51 TrialAcute Coronary Syndrome (ACS)MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2008-002708-25-LVJanssen-Cilag International N.V.16,000